Oncology

Oncological Biosimilars Shown to Be as Safe as Their Reference Products

August 13th 2023

By Gillian McGovern

Article

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

Sintilimab Plus Bevacizumab Biosimilar vs Avastin Is Cost-Effective in HCC

August 8th 2023

By Skylar Jeremias

Article

A Chinese study proved that combination therapy with sintilimab and a bevacizumab biosimilar was cost-effective enough in patients with hepatocellular carcinoma (HCC) to warrant use of the biosimilar over the reference product (Avastin) without compromising safety or efficacy.

Despite Global Increase in Amjevita Sales, US Sales Dropped 63%

August 5th 2023

By Skylar Jeremias

Article

Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.

Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer

July 31st 2023

By Skylar Jeremias

Article

Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.

Reference Bevacizumab and Proposed Biosimilar Show High Similarity

July 27th 2023

By Justina Petrullo

Article

Reference bevacizumab and proposed biosimilar (BAT1706) demonstrate high similarity to each other.

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

July 19th 2023

By Skylar Jeremias

Article

The second edition of Samsung Bioepis’ Biosimilar Market Report shows strong correlation between biosimilar usage and decreased drug prices, proving that biosimilars are delivering on the promise of savings and price erosion.

Biosimilars Can Expand Treatment Access for Traditionally Excluded Communities

July 18th 2023

By Justina Petrullo

Article

Biosimilars may be able to increase treatment access for traditionally excluded communities, especially racial and ethnic minority populations.

Dose Rounding Can Reduce Drug Waste Costs Associated With Reference, Biosimilar Bevacizumab

June 19th 2023

By Skylar Jeremias

Article

Implementing strategies, such as dose rounding, can offset the impact of drug waste and reduce the total cost of care for value-based programs, according to a recent study of practices participating in the Oncology Care Model.

Dr Ryan Haumschild Shares How Oncology Practice, Payer Collaboration Can Increase Biosimilar Adoption

June 18th 2023

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how oncology practices can work better with payers to increase biosimilar adoption and how those collaborations can be applied to other disease areas, such as immunology and neurology.

Increased Competition Is Lowering Trastuzumab Prices

June 14th 2023

By Skylar Jeremias

Article

After 8 years of trastuzumab biosimilar competition and slow uptake, a new report shows that trastuzumab biosimilar discounts from the reference product (Herceptin) doubled between 2019 and 2022.